News

AI-525 is a preclinical-stage injectable formulation of celecoxib using Acusphere’s proprietary Hydrophobic Drug Delivery System technology. The transaction is expected to close in approximately 10 days. The $15

Pitavastatin is a novel ‘statin’ for the treatment of hypercholesterolaemia. The request for approval dossier was submitted by Kowa Pharmaceutical Europe (KPE) at the end of August 2008

Previously, the company announced that the US Phase II clinical trial had been suspended in order to investigate an incident of post-operative bleeding. This event met the stopping

The terms of the proposed offer were not disclosed but include a stock for stock exchange and the assumption of liabilities with a potential total deal value in

The Ring trial is a randomized, double-blind, placebo-controlled study evaluating approximately 200 patients with refractory gastrointestinal stromal tumors (GIST) in over 20 countries and 50 sites worldwide. Patients

The lawsuit is based upon an abbreviated new drug application (ANDA) filed by Barr requesting approval to market and sell a generic version of Oxytrol to be sold

Under the proposed agreement, RecoverCare will purchase products from Ivivi, who in return will be responsible for providing initial training and ongoing technical and warranty support. In addition,

Under the terms of the agreement, GlaxoSmithKline will exclusively promote Diastat and Diastat AcuDial to US physicians in 2009, with an option to extend the term by mutual

With the approved CE Mark for Uracyst already in place for the European market, Eczacibasi Ilac Pazarlama (EIP) has agreed to obtain all necessary regulatory approvals at its